S&P 500   4,561.87 (+0.15%)
DOW   35,523.19 (+0.30%)
QQQ   391.01 (+0.21%)
AAPL   189.43 (-0.51%)
MSFT   379.48 (-0.84%)
META   333.25 (-1.69%)
GOOGL   135.48 (-1.25%)
AMZN   146.99 (-0.03%)
TSLA   247.42 (+0.28%)
NVDA   482.15 (+0.82%)
NIO   7.22 (+0.14%)
BABA   74.97 (-2.31%)
AMD   124.51 (+2.05%)
T   16.31 (+0.80%)
F   10.66 (+2.80%)
MU   76.75 (+0.83%)
CGC   0.57 (+4.96%)
GE   119.06 (+0.18%)
DIS   92.99 (+0.53%)
AMC   7.26 (+8.36%)
PFE   30.08 (+1.31%)
PYPL   58.37 (-0.17%)
XOM   103.57 (-0.32%)
S&P 500   4,561.87 (+0.15%)
DOW   35,523.19 (+0.30%)
QQQ   391.01 (+0.21%)
AAPL   189.43 (-0.51%)
MSFT   379.48 (-0.84%)
META   333.25 (-1.69%)
GOOGL   135.48 (-1.25%)
AMZN   146.99 (-0.03%)
TSLA   247.42 (+0.28%)
NVDA   482.15 (+0.82%)
NIO   7.22 (+0.14%)
BABA   74.97 (-2.31%)
AMD   124.51 (+2.05%)
T   16.31 (+0.80%)
F   10.66 (+2.80%)
MU   76.75 (+0.83%)
CGC   0.57 (+4.96%)
GE   119.06 (+0.18%)
DIS   92.99 (+0.53%)
AMC   7.26 (+8.36%)
PFE   30.08 (+1.31%)
PYPL   58.37 (-0.17%)
XOM   103.57 (-0.32%)
S&P 500   4,561.87 (+0.15%)
DOW   35,523.19 (+0.30%)
QQQ   391.01 (+0.21%)
AAPL   189.43 (-0.51%)
MSFT   379.48 (-0.84%)
META   333.25 (-1.69%)
GOOGL   135.48 (-1.25%)
AMZN   146.99 (-0.03%)
TSLA   247.42 (+0.28%)
NVDA   482.15 (+0.82%)
NIO   7.22 (+0.14%)
BABA   74.97 (-2.31%)
AMD   124.51 (+2.05%)
T   16.31 (+0.80%)
F   10.66 (+2.80%)
MU   76.75 (+0.83%)
CGC   0.57 (+4.96%)
GE   119.06 (+0.18%)
DIS   92.99 (+0.53%)
AMC   7.26 (+8.36%)
PFE   30.08 (+1.31%)
PYPL   58.37 (-0.17%)
XOM   103.57 (-0.32%)
S&P 500   4,561.87 (+0.15%)
DOW   35,523.19 (+0.30%)
QQQ   391.01 (+0.21%)
AAPL   189.43 (-0.51%)
MSFT   379.48 (-0.84%)
META   333.25 (-1.69%)
GOOGL   135.48 (-1.25%)
AMZN   146.99 (-0.03%)
TSLA   247.42 (+0.28%)
NVDA   482.15 (+0.82%)
NIO   7.22 (+0.14%)
BABA   74.97 (-2.31%)
AMD   124.51 (+2.05%)
T   16.31 (+0.80%)
F   10.66 (+2.80%)
MU   76.75 (+0.83%)
CGC   0.57 (+4.96%)
GE   119.06 (+0.18%)
DIS   92.99 (+0.53%)
AMC   7.26 (+8.36%)
PFE   30.08 (+1.31%)
PYPL   58.37 (-0.17%)
XOM   103.57 (-0.32%)

Aptose Biosciences Stock Price, News & Analysis (NASDAQ:APTO)

$2.52
+0.29 (+13.00%)
(As of 02:14 PM ET)
Compare
Today's Range
$2.30
$2.60
50-Day Range
$2.14
$3.32
52-Week Range
$2.14
$11.55
Volume
35,836 shs
Average Volume
30,117 shs
Market Capitalization
$19.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.67

Aptose Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,394.7% Upside
$37.67 Price Target
Short Interest
Healthy
0.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Aptose Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$53,380 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($7.83) to ($5.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

344th out of 949 stocks

Biological Products, Except Diagnostic Industry

53rd out of 161 stocks


APTO stock logo

About Aptose Biosciences Stock (NASDAQ:APTO)

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

APTO Stock Price History

APTO Stock News Headlines

The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Aptose Biosciences: Q3 Earnings Insights
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Oppenheimer Reaffirms Their Buy Rating on Aptose Biosciences (APTO)
Expert Ratings for Aptose Biosciences
Closing Bell: Aptose Biosciences Inc down on Tuesday (APS)
Aptose Biosciences (NASDAQ: APTO)
APTO - Aptose Biosciences Inc.
See More Headlines
Receive APTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/23/2023
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/28/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APTO
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$37.67
High Stock Price Target
$120.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+1,589.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-41,820,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.03 per share

Miscellaneous

Free Float
6,824,000
Market Cap
$16.81 million
Optionable
Optionable
Beta
1.43
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. William G. Rice Ph.D. (Age 59)
    Chairman, Pres & CEO
  • Mr. Gregory K. Chow CPA (Age 45)
    MBA, BA, Sr. VP, CFO & Principal Accounting Officer
  • Mr. Ernest Kitt B.S.
    M.S, VP of Devel. & Technical Operations
  • Dr. Stephen B. Howell (Age 73)
    Chief Medical Officer
  • Mr. Peter Murray
    Director of Clinical Devel.














APTO Stock Analysis - Frequently Asked Questions

Should I buy or sell Aptose Biosciences stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" APTO shares.
View APTO analyst ratings
or view top-rated stocks.

What is Aptose Biosciences' stock price target for 2024?

6 Wall Street research analysts have issued 12 month target prices for Aptose Biosciences' shares. Their APTO share price targets range from $12.00 to $120.00. On average, they predict the company's stock price to reach $37.67 in the next twelve months. This suggests a possible upside of 1,394.7% from the stock's current price.
View analysts price targets for APTO
or view top-rated stocks among Wall Street analysts.

How have APTO shares performed in 2023?

Aptose Biosciences' stock was trading at $8.70 at the beginning of 2023. Since then, APTO stock has decreased by 71.0% and is now trading at $2.52.
View the best growth stocks for 2023 here
.

Are investors shorting Aptose Biosciences?

Aptose Biosciences saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 30,500 shares, a drop of 27.2% from the October 31st total of 41,900 shares. Based on an average trading volume of 37,400 shares, the days-to-cover ratio is currently 0.8 days. Currently, 1.0% of the company's shares are sold short.
View Aptose Biosciences' Short Interest
.

When is Aptose Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our APTO earnings forecast
.

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (NASDAQ:APTO) posted its quarterly earnings results on Thursday, March, 23rd. The biotechnology company reported ($1.65) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.65). During the same quarter in the previous year, the business earned ($4.05) EPS.

When did Aptose Biosciences' stock split?

Aptose Biosciences's stock reverse split before market open on Tuesday, June 6th 2023. The 1-15 reverse split was announced on Tuesday, June 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO?

8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend.

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX).

Who are Aptose Biosciences' major shareholders?

Aptose Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sigma Planning Corp (1.93%), Annandale Capital LLC (0.99%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bernd R Seizinger, Denis R Burger, Donald R Jr Wilson, Erich Platzer, Rafael Bejar, Warren Whitehead and William G Rice.
View institutional ownership trends
.

How do I buy shares of Aptose Biosciences?

Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:APTO) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -